Biosyn corp news

It goes both ways: The multi-directional relationships between selenium levels and breast cancer.

It goes both ways: The multi-directional relationships between selenium levels and breast cancer.

Common knowledge be damned. Despite a healthy lifestyle, regular cancer screening exams, efforts to balance work, family and self-realization comes the diagnosis: breast cancer. Mammograms, biopsies, more blood tests to inform the therapeutic strategy. Then, the prognosis. Many factors affect the expected outcome of cancer therapy. These include age, tumor size, tumor stage, lymph node involvement, overweight among many others.

Read more...

biosyn’s CEO proud about Panama. selenase® T peroral now approved for sale there.

biosyn’s CEO proud about Panama. selenase® T peroral now approved for sale there.

At the beginning of the year, biosyn announced that Panama’s National Department of Pharmacy and Drugs at its Ministry of Health had approved selenase® T peroral (500 µg). This new marketing authorization for the oral form of selenium comes in addition to the previous approval by the Central American country of selenase 500 μg injection solution. These pharmaceuticals are indicated to treat clinically proven selenium deficiency that cannot be compensated by nutritional sources.

Read more...

A tale of two subunits: KLH 1 and KLH 2 in Immucothel

A tale of two subunits: KLH 1 and KLH 2 in Immucothel

Themes of earthly duality have been inspirations throughout history, for example, compelling Charles Dickens to write about two contrasting cities, Goethe’s character Faust to lament the two competing souls in his breast and Shakespeare’s Hamlet to confront the choice between life and death. The exploration of dichotomies by novelists and poets has produced great works of literature and expanded our insights into the human situation. The same holds true for researchers and science.

Read more...

Pandemic proportions with a complexity of multiple risks and indicators

Pandemic proportions with a complexity of multiple risks and indicators

No other co-condition is such a compounder and confounder of morbidity and mortality for every and any incurrent disease. Its inherent risk runs the entire gamut from cancer, heart disease, Alzheimer’s, inflammatory bowel disease, clinical depression, infections and now even to COVID-19. The likelihood of a worse outcome is elevated exponentially by this condition. Did you say “smoking”? No, it’s the epidemic of obesity that has rapidly spread around the globe in the past decades.

Read more...

KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

The memory loss disorder eponymously called Alzheimer's burdens around 44 million people worldwide, according to the statistics reported by “Alzheimer’s News Today”. The prevalence of this neurodegenerative disease is as pathologically progressive as is its clinical course. Absent any cure or any way to stop or slow progression, the only options are symptomatic treatments and coping strategies for patients and their loved ones. Therefore, many committed researchers have long set their sights on developing a vaccine to ward off the disease’s neurodegenerative mental decline.

Read more...

Mechanism for stimulating anti-tumor immune responses: How Keyhole Limpet Hemocyanin (KLH) antibodies detect and destroy bladder cancer cells

Numerous oligosaccharides are attached to the surface of the KLH molecule and account for about 4% of its molecular mass. With their intricate topology, these oligosaccharides contribute to KLH’s strong immunogenicity. Although not completely elucidated, different mechanisms of action are at play: non-specific stimulation of the immune system, stimulation of cytotoxic T cells and induction of anti-tumoral antibodies. KLH antibodies can bind to the Thomsen-Friedenreich antigens associated with cancer progression and metastasis on bladder carcinoma cells. The reaction of KLH antibody with Thomsen-Friedenreich antigen leads to phagocytosis and dissolution of the tumor cell. Immunocyanin, the main ingredient in IMMUCOTHEL® for the recurrence prevention of superficial urinary bladder carcinoma, is derived from KLH.

Read more...

German know-how. American ingenuity. Good Manufacturing Practice for global hemocyanin products thrives in California.

Since its founding in Carlsbad, California in 1995, biosyn Corporation has driven the development, manufacturing and marketing of hemocyanin and immunocyanin products forward. With German know-how, American ingenuity and the help of a California resident, the first hemocyanin product was approved in 1997. Ever since, biosyn has been the leading manufacturer of high-quality, clinical-, GMP- and research-grade hemocyanin products extracted from the Giant Keyhole Limpet. The anticancer drugs, immunotherapeutics and carrier-proteins for vaccines evolved from this combination benefit patients around the globe.

To learn more about Good Manufacturing Practice (GMP) at biosyncorp, visit biosyncorp.com/about-us/

Hope is the color blue. The unique IMMUCOTHEL® from the keyhole limpet indicated for the prevention of superficial bladder cancer recurrence.

What to do when the standard fails? Wasn't it enough that the patient suffered from superficial bladder cancer and now a post-TUR recurrence? After standard therapies were contraindicated, have been exhausted or were not tolerated in the first place, second-line treatment with IMMUCOTHEL® is indicated to prevent recurrences in superficial bladder cancer. This immunotherapeutic from biosyn is a safe, efficacious and well-established alternative to BCG. Thanks to its high tolerability and low rate of side effects, patients experience much less distress with IMMUCOTHEL®.

Read more...